SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired agilon health, inc. (NYSE: AGL) securities between February 26, 2025 and August 4, 2025. agilon describes itself as the "trusted partner empowering physicians to transform health care in our communities."For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is ...

SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired agilon health, inc. (NYSE: AGL) securities between February 26, 2025 and August 4, 2025. agilon describes itself as the "trusted partner empowering physicians to transform health care in our communities."For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is ...

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of all persons or entities who purchased or otherwise acquired Agilon Health, Inc. (“Agilon” or the “Company”) (NYSE: AGL) securities between February 26, 2025, and August 4, 2025. The Complaint alleges that (i) Defendants recklessly issued guidance for 2025 that they knew or should have known ...

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds purchasers or acquirers of agilon health, inc. (“Agilon” or the “Company”) (NYSE: AGL) that a federal securities class action has been filed on behalf of investors who purchased Agilon between February 6, 2025 and August 4, 2025, inclusive (the “Class Period”). Investors have until March 2, 2026 to seek appointments as lead plaintiff. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION The filed compl ...

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against agilon health, inc. (“Agilon” or the “Company”) (NYSE: AGL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Agilon and certain of its offic ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In agilon health To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in agilon health between February 26, 2025 and August 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Jan. 6, 2026 /PRNewswire/ -- Fa ...

Core Viewpoint - A class action lawsuit has been filed against Agilon Health, Inc. for allegedly making false and misleading statements regarding its financial guidance and business operations during the Class Period from February 26, 2025, to August 4, 2025 [3][7]. Allegation Details - The lawsuit claims that defendants issued guidance for 2025 that they knew or should have known was unattainable due to significant industry challenges [3]. - It is alleged that defendants overstated the immediate positive financial impact from strategic actions taken to mitigate risks [3]. - As a result, statements made about Agilon's business, operations, and prospects were materially false and misleading throughout the Class Period [3]. Next Steps - Investors who purchased Agilon shares and suffered losses are encouraged to contact the law firm for more information regarding their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is March 2, 2026 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation, including securities and commercial cases [5]. - The firm operates nationwide and handles cases in both federal and state courts [5].

SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired agilon health, inc. (NYSE: AGL) securities between February 26, 2025 and August 4, 2025. Agilon describes itself as the "trusted partner empowering physicians to transform health care in our communities." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is I ...

NEW YORK--(BUSINESS WIRE)---- $AGL #AGL--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against agilon health, inc. ("agilon†or the "Company†) (NYSE: AGL) and reminds investors of the March 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has. ...

Core Viewpoint - A class action lawsuit has been filed against Agilon Health, Inc. for alleged violations of securities laws, specifically related to misleading statements made by the company regarding its financial guidance and strategic actions [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Agilon's securities between February 26, 2025, and August 4, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Agilon - The complaint alleges that Agilon made false and misleading statements to the market, particularly regarding its 2026 guidance, which was deemed unrealistic [4]. - The company is accused of overstating the effectiveness of its strategic actions aimed at reducing risk, leading to materially misleading public statements throughout the class period [4]. - As a result of the revelations about Agilon's true situation, investors reportedly suffered financial damages [4].